VP Pharmaceutical Development
Sound Pharmaceuticals, Inc.
Seattle, WA, United States
G. Michael Wall, PhD, VP Pharmaceutical Development, Sound Pharmaceuticals, Inc., is a proven leader in the pharmaceutical development of drug products. Expertise spans the entire lifecycle of pharmaceutical development from preclinical research to global regulatory approval and product launch, with special expertise in pharmaceutical formulations and manufacturing. Previously at Alcon Laboratories, Inc., Wall launched an otolaryngology research and development program that led to the approval of several novel drug products, including Patanase® Nasal Spray and Ciprodex® Otic Suspension. Patanase® Nasal Spray is the most widely prescribed antihistamine nasal spray by U.S. pediatricians for the relief of seasonal allergies. Ciprodex® Otic Suspension was the first topical combination antibiotic/corticosteroid drug product approved by the United States Food and Drug Administration for the treatment of acute external and middle ear infections and is the most widely prescribed branded eardrop by U.S. pediatricians and otolaryngologists. Furthermore, Wall led development for otic products including CIPRO® HC, SOFENZ-TM and XTORO®, contributed to the development of ophthalmic products such as AZOPT®, BETOPTIC® S, CILOXAN®, FLAREX®, IOPIDINE®, Levobetaxolol, PATADAY®, PATANOL®, VEXOL®, VIGAMOX®, TRAVATAN®, and dermatological products such as DESONIDE® and DIFFERIN®. Wall is a Scientific Fellow of AAO-HNS.
SPI-1005 (Ebselen) Reduces Low Frequency Hearing Loss After Cochlear Implantation in Guinea Pigs
Sunday, September 29, 2024
2:48 PM – 2:54 PM EDT
Disclosure information not submitted.